InflaRx (NASDAQ:IFRX) Trading 10.4% Higher – Time to Buy?

InflaRx N.V. (NASDAQ:IFRX) shares shot up 10.4% on Monday . The company traded as high as $1.0050 and last traded at $0.9740. 633,932 shares changed hands during mid-day trading, an increase of 7% from the average session volume of 589,864 shares. The stock had previously closed at $0.8821.

Wall Street Analyst Weigh In

IFRX has been the subject of a number of analyst reports. Guggenheim increased their target price on InflaRx from $10.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of InflaRx in a research report on Tuesday, December 30th. Wall Street Zen cut shares of InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down previously from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.50.

InflaRx Price Performance

The company has a market capitalization of $65.38 million, a PE ratio of -1.43 and a beta of 1.46. The stock has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.16.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts predict that InflaRx N.V. will post -1.04 EPS for the current fiscal year.

Institutional Trading of InflaRx

Several large investors have recently modified their holdings of IFRX. Bank of America Corp DE purchased a new position in shares of InflaRx during the 3rd quarter worth approximately $3,316,000. Woodline Partners LP acquired a new stake in InflaRx during the 1st quarter valued at $766,000. Adage Capital Partners GP L.L.C. purchased a new position in InflaRx during the second quarter worth $262,000. ADAR1 Capital Management LLC purchased a new position in InflaRx during the third quarter worth $214,000. Finally, Susquehanna International Group LLP acquired a new position in shares of InflaRx in the third quarter worth $190,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.